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Abstract
Within the GEN-COVID Multicenter Study, biospecimens from more than 1000 SARS-CoV-2 positive individuals have
thus far been collected in the GEN-COVID Biobank (GCB). Sample types include whole blood, plasma, serum, leukocytes,
and DNA. The GCB links samples to detailed clinical data available in the GEN-COVID Patient Registry (GCPR). It
includes hospitalized patients (74.25%), broken down into intubated, treated by CPAP-biPAP, treated with O2
supplementation, and without respiratory support (9.5%, 18.4%, 31.55% and 14.8, respectively); and non-hospitalized
subjects (25.75%), either pauci- or asymptomatic. More than 150 clinical patient-level data fields have been collected and
binarized for further statistics according to the organs/systems primarily affected by COVID-19: heart, liver, pancreas,
kidney, chemosensors, innate or adaptive immunity, and clotting system. Hierarchical clustering analysis identified five main
clinical categories: (1) severe multisystemic failure with either thromboembolic or pancreatic variant; (2) cytokine storm
type, either severe with liver involvement or moderate; (3) moderate heart type, either with or without liver damage; (4)
moderate multisystemic involvement, either with or without liver damage; (5) mild, either with or without hyposmia. GCB
and GCPR are further linked to the GCGDR, which includes data from whole-exome sequencing and high-density SNP
genotyping. The data are available for sharing through the Network for Italian Genomes, found within the COVID-19
dedicated section. The study objective is to systematize this comprehensive data collection and begin identifying multi-organ
involvement in COVID-19, defining genetic parameters for infection susceptibility within the population, and mapping
genetically COVID-19 severity and clinical complexity among patients.
Introduction
The GEN-COVID
Multicenter Study was designed to collect and systematize
biological samples and clinical data across multiple hospi-
tals and healthcare facilities in Italy with the purpose of
deriving patient-level phenotypic and genotypic data, and
the specific intention to make samples and data available to
COVID-19 researchers globally. To reach these aims, the
project collected and organized high-quality samples and
data whose integrity was assured and could be readily
accessed and processed for COVID-19 research using
existing interoperability standards and tools. To this end, a
GEN-COVID Biobank (GCB) and a GEN-COVID Patient
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Registry (GCPR) were established utilizing already existing
biobanking and patient registry infrastructure. The collec-
tion of samples and data are now utilized in the GEN-
COVID Multicenter Study for generating Genotyping
(GWAS) and whole-exome sequencing (WES) results. This
study also works collaboratively with other genomic studies
on COVID-19. The data resulting from these studies are
then stored and made available through the GEN-COVID
Genetic Data Repository (GCGDR). All samples and data
have also been systematized in accordance with the FAIR
(findability, accessibility, interoperability, and reuse) data
principles [1] to promote their international availability and
use for COVID-19 research.
The outbreak of the coronavirus disease 2019 (COVID-
19), the Severe Acute Respiratory Syndrome caused by
coronavirus SARS-CoV-2, that first appeared in December
2019 in Wuhan, Huanan, Hubei Province of China,
has resulted in millions of cases worldwide within a few
short months, and rapidly evolved into a real pandemic [2].
The COVID-19 pandemic represents an enormous chal-
lenge to the world’s healthcare systems. Among the Eur-
opean countries, Italy was the first to experience the
epidemic wave of SARS-CoV-2 infection, accompanied
by a severe clinical picture and a mortality rate reaching
14%. In Italy, as of July 16th, 2020, there were 243,506
confirmed COVID-19 cases and 34,997 related deaths
reported [3].
The disease is characterized by a highly heterogeneous
phenotypic response to SARS-CoV-2 infection, with the
large majority of infected individuals having only mild or
even no symptoms. However, the severe cases can rapidly
evolve toward a critical respiratory distress syndrome and
multiple organ failure. The symptoms of COVID-19 range
from fever, cough, sore throat, congestion, and fatigue to
shortness of breath, hemoptysis, pneumonia followed by
respiratory disorders, and septic shock [4].
The overburdened healthcare infrastructure and the
working conditions within healthcare centers are tre-
mendously challenging. Direct patient care is given the
highest priority. Focus is concentrated on monitoring
infection evolution in terms of the number of new cases
and the number of deaths. Disease severity is also an
important parameter that is being continually evaluated,
with a current focus on patients experiencing serious
pulmonary disease and other life-threatening conditions.
Although patient care is the first priority, in the public
health emergency situation brought on by the COVID-19
pandemic, it is also of the utmost importance to collect,
process, and share with rapidity and confidence human
biological materials, clinical data, and study outcomes.
The best suited tool to address this need and accelerate
research on COVID-19 is an accessible, high-quality
biobank with associated clinical data and the necessary
tools to guarantee interoperability with other biobanks and
databanks.
This paper addresses the main aim of the project: the
collection and systematization of human biological materi-
als, clinical data stored in a patient registry, and derived
patient-level genetic data. The paper addresses the methods
for sample and data collection, and the systematization of
the samples and data for research purposes. As COVID-19
increasingly reveals itself as a multisystemic disease, the
purpose of this data collection is to include the most rele-
vant clinical variables that identify multi-organ involvement
as well as identify the genetic determinants of virus–host
interaction, so as to holistically disclose the effect of
COVID-19 over several physiological subsystems. In the
present paper, the samples and the complete datasets are
then used within the GEN-COVID Multicenter Study for
identifying multi-organ involvement in COVID-19, defin-
ing genetic parameters for infection susceptibility within the
population, and mapping genetically COVID-19 severity
and clinical complexity among patients. Going forward, the
main challenge will be to define the genetic parameters for
infection susceptibility within specific populations in order
to be able to map and identify genetically COVID-19




The purpose of the GEN-COVID Multicenter Study is to
make the best use of the widest possible sets of patient data
and genetic material in order to identify potential links
between patient genetic variation and clinical variability,
patient presentation, and disease severity. By exposing the
potential links between genetic variability and disease
variability, the study believes it can contribute to improved
patient-level diagnostics, prognosis, and personalized
treatment of COVID-19. To achieve this overall aim, the
following specific objectives are being pursued: (1) to
perform sequencing (WES) on DNA of 2000 COVID-19
patient samples [performed by the University of Siena
(UNISI)]; (2) to perform genotyping (GWAS) on DNA of
2000 COVID-19 patients [performed by the Institute for
Molecular Medicine of Finland (FIMM)]; (3) to associate
the host genetic data obtained on 2000 COVID-19 patients
with severity and prognosis; (4) to share phenotypic data
and samples across the GEN-COVID consortium platform
as well as in cooperation with research institutions and
national platforms through the GEN-COVID Disease Reg-
istry and Biobank; (5) to share genetic data through the
Network of Italian Genome (NIG, http://www.nig.cineca.it/,
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NIG database, http://nigdb.cineca.it) at CINECA, the largest
Italian computing center.
Planned key deliverables of the project are (1) to develop
a state-of-the-art Patient Registry and Biobank for COVID-
19 clinical research with access for academic and industry
partners; (2) to understand the genetic and molecular basis
of susceptibility to SARS-CoV-2 infection and (suscept-
ibility to a potentially more severe clinical outcome [prog-
nosis] within 12 months); and (3) to understand the genetic
profile of patients. The overall aim is to contribute to the
rapid identification of medicines to be repurposed for per-
sonalized therapeutic approaches that demonstrate greater
efficacy against the COVID-19 virus. As the initial starting
point of this process, the ACE2 gene has already been
extensively investigated in the Italian population [5].
The GEN-COVID Multicenter Study includes a network
of 22 Italian hospitals, 13 from Northern Italy, 5 from
Central Italy, and 4 from Southern Italy. It also includes
local healthcare units and departments of preventative
medicine (https://sites.google.com/dbm.unisi.it/gen-covid).
The network continues to grow as more hospitals and
healthcare centers express an interest in contributing sam-
ples and data. It started its activity on March 16, 2020,
following approval by the Ethical Review Board of the
Promoter Center, University of Siena (Protocol n. 16929,
approval dated March 16, 2020). Written informed consent
was obtained from all individuals who contributed samples
and data. Detailed clinical and laboratory characteristics
(data), specifically related to COVID-19, were collected for
all subjects.
Study participants and recruitment
In order to ensure a collection that could be, as much as
possible, comprehensive and representative of the Italian
population, hospitals from across Italy, local healthcare
units, and departments of preventive medicine have been
involved in collecting samples and associated patient-level
data for the GEN-COVID Multicenter Study. The inclusion
criteria for the study are PCR-positive SARS-CoV-2
infection, age ≥18 years, and appropriately given informed
consent that includes detailed information about the study,
maintaining the confidentiality of personal data. In addition
to the samples collection, an extensive questionnaire is used
to assess disease severity and collect basic demographic
information from each patient (Supplementary Table 1).
As of July 16, 2020, we have collected samples and data
from 1033 individuals (1021 without family ties and 12
with family relations). All were positively diagnosed with
SARS-CoV-2 and representing a wide range of disease
severity, rang from hospitalized patients with severe
COVID-19 disease to asymptomatic individuals. Infection
status was confirmed by SARS-CoV-2 viral RNA
polymerase-chain-reaction (PCR) test collected at least from
nasopharyngeal swabs. Recruitment remains ongoing with
the goal of including samples and data from 2000 indivi-
duals by the end of September 2020. So far recruiting an
averages of 200 patients per week.
Data collection and storage
The GEN-COVID registry was designed in order to guar-
antee data accuracy and, at the same time, to ensure ease of
data entry in order to facilitate compliance and save clin-
icians time. The highest data integrity and data privacy
standards, with reference to the EU General Data Protection
Regulation (GDPR) [6], were also built into the training for
personnel. Samples and data were collected and system-
atized in order to meet the FAIR Data Principles
requirements.
The socio-demographic information included sex, age,
and ethnicity. Information about family history, (pre-exist-
ing) chronic conditions, and SARS-CoV-2 related symp-
toms were collected through a detailed core clinical
questionnaire as previously reported [7]. This clinical data
were continually updated as new information appeared
regarding COVID-19 (Supplementary Table 1). More than
150 clinical items have been collected and synthesized in a
binary mode for each involved organ/system: heart, liver,
pancreas, kidney, and olfactory/gustatory and lymphoid
systems. The collection and organizing methodologies
allowed for rapid statistical analysis. Data were handled and
stored in accordance with the EU GDPR [6].
Peripheral blood samples in ethylenediamine tetraacetic
acid-containing tubes were collected for all subjects.
Genomic DNA was centrally isolated from peripheral blood
samples using the MagCore®Genomic DNA Whole Blood
Kit (Diatech Pharmacogenetics, Jesi, Italy) according to the
manufacturer’s protocol at the Promoter Center. For all
subjects, aliquots of plasma and serum are also available.
Whenever possible, leukocytes were isolated from whole
blood by density gradient centrifugation and stored in
dimethyl sulfoxide solution and frozen using liquid nitro-
gen. For the majority of cohort, swab specimens are also
available and stored at the reference hospitals.
Genetic data from GWAS and WES were generated for
all patients. The generation of such a massive amount of
sequencing data required sufficient computing resources
able to store and analyze large quantities of data. For this
purpose, GEN-COVID took advantage of the University of
Siena’s participation in the Network for Italian Genomes
(NIG, http://www.nig.cineca.it/, NIG database, http://nigdb.
cineca.it/), which collects genome sequencing data from the
Italian population. NIG has a specific agreement with
CINECA, the largest computing center in Italy and one of
the largest in Europe, for the use of the CINECA facility for
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the storage and analysis of data. Data upload followed
quality and regulatory requirements already in place to
ensure adequate uniformity and homogeneity levels. Data
were formatted to meet the requirements of the FAIR Data
Principles and thus made interoperable with other FAIR
omics data and reference databases.
Collected laboratory and instrumental data
A continuous quantitative respiratory score, the PaO2/FiO2
[Partial pressure of oxygen/Fraction of inspired oxygen
ratio (P/F)] was assigned to each patient as an indicator of
the respiratory involvement. Taking the normal value >300
as the threshold, we defined four grades of severity score
for the PaO2/FiO2 ratio: P/F less than or equal to 100,
between 101 and 200, between 201 and 300, and greater
than 300. A P/F value is not available for the non-
hospitalized subjects because the test is only performed in
hospitalized patients when needed. Heart involvement was
considered on the basis of one or more of the following
abnormal data: a cardiac Troponin T (cTnT) value higher
than the reference range (<15 ng/L) (indicative of ischemic
disorder), an increase in the N-terminal (NT)-pro hormone
BNP (NT-proBNP) value (reference value <88 pg/mL for
males and <153 pg/mL for females) (indicative of heart
failure), and the presence of arrhythmias (indicative of
electric disorder). Hepatic involvement was defined on the
basis of a clear liver enzymes elevation as glutamate-
pyruvate transaminase (GPT) and glutamate-oxaloacetate
transaminase (GOT) higher than the gender specific refer-
ence value (for GPT < 41 UI/L in males and <31 UI/L in
females; for GOT < 37 UI/L in males and <31 UI/L in
females). Pancreatic involvement was considered on the
basis of pancreatic enzymes as pancreatic amylase (PA)
and lipase (PL) higher or lower than their specific reference
range (13–53 UI/l for PA and 13–60 UI/l per PL). Kidney
involvement was defined in the presence of a creatinine
value higher than the gender specific reference value
(0.7–1.20 mg/dL in males and 0.5–1.10 mg/dL in females).
Lymphoid system involvement was designated as Natural
killer (NK) cells and/or peripheral CD4+ T cells below
reference value (NK cells > 90 cell/µL (mm3); CD4+
T cells > 400 cell/µL (mm3)). For each patient a numerical
grading for the olfactory and gustatory dysfunction was
defined through a clinical questionnaire, administered by
ENT specialists. D-Dimer values of >10× with or without
low Fibrinogen level, were used to interpret the involve-
ment of the blood clotting system. Interleukin 6 (IL6),
lactate dehydrogenase (LDH), and c-reactive protein (CRP)
values above the reference range (<0.5 mg/dL for CRP and
135–225 UI/l in males and 135–214 UI/l in females for
LDH) were used to determine pro-inflammatory cytokines
system involvement.
Whole-exome sequencing
WES with at least 97% coverage at 20× was performed
using the Illumina NovaSeq6000 System (Illumina, San
Diego, CA, USA).
Sample preparation was performed following the Nex-
tera Flex for Enrichment manufacturer protocol. The
workflow uses a bead-based transposome complex to tag-
ment genomic DNA, which is a process that fragments
DNA and then tags the DNA with adapter sequences in one
step. After it is saturated with input DNA, the bead-based
transposome complex fragments a set number of DNA
molecules. This fragmentation provides flexibility to use a
wide DNA input range to generate normalized libraries of
consistent tight fragment size distribution. Following tag-
mentation, a limited-cycle PCR adds adapter sequences to
the ends of a DNA fragment. A subsequent target enrich-
ment workflow is then applied. Following pooling, the
double stranded DNA libraries are denatured and biotiny-
lated Illumina CEX Panel probes are hybridized to the
denatured library fragments. After hybridization, Strepta-
vidin Magnetic Beads then capture the targeted library
fragments within the regions of interest. The captured and
indexed libraries are eluted from beads and further ampli-
fied before sequencing. The WES analysis was performed
on the Illumina NovaSeq6000 System (Illumina San Diego,
CA, USA) according to the NovaSeq6000 System Guide.
Genotyping
Genotyping data on 700,000 genetic markers were obtained on
genomic DNA using the Illumina Global Screening Array
(Illumina) according to the manufacturer’s protocol. Homo
sapiens (human) Genome Reference Consortium Human Build
38 (GRCh38) was used. Quality checks (SNP calling quality,
cluster separation, and Mendelian and replication error) were
done using GenomeStudio analysis software (Illumina). The
computer package Plink v1.90 [8] was used to process 700k
SNP-genotyping data and to calculate SNP genotype statistics.
Statistical analysis
Descriptive statistics were calculated to determine the dis-
tribution of clinical features by sex, age, and ethnicity. Chi-
square tests were used to evaluate the statistical association
between the clinical severity of the disease (from no hospi-
talization to intubation) and the categorical clinical variables:
gender, ethnicity, blood group, respiratory severity, taste/
smell involvement, heart involvement, liver involvement,
pancreas involvement, kidney involvement, lymphoid invol-
vement, cytokines trigger, D-dimer, and number of comor-
bidities. A linear regression model was used to test the
statistical association between COVID-19 severity and age.
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The variability within clinical features and their relative
relationships have been summarized and described by principal
component analysis (PCA). Only numerical variables with a
missing rate lower than 50% were selected; these included:
hyposmia, neutrophils, CRP, fibrinogen, LDH, D-dimer, and
number of comorbidities. Missing data were defined equal to
the most common value among the k-neighbors (k= 5) [9], as
defined by Gower distances [10]. After imputation, variables
were centered and scaled prior to PCA. Descriptive statistics,
chi-square tests, linear regression, and PCA were performed
with the R environment for statistical computing [11].
A descriptive analysis of the phenotypes by using
a hierarchically clustered heatmap was performed. In
particular, both patients and phenotypes are clusterized
with the agglomerative hierarchical clustering methodology,
where the chosen metric is the hamming distance
and the linkage criterion is the “average” one (unweighted
pair group method with arithmetic mean, UPGMA).
The corresponding dendrograms of the clusterization are
reported in the upper and in the left part of the heat plot.
Then the information on the grading of severity of the
patients is added a posteriori on the left strip. The resulting
plot is obtained with the Python Seaborn package.
Results
The GEN-COVID Multicenter Study, through a cooperative
and carefully curated moded of sample and data collection,
has employed rigorous analyses to achieve phenotypic and
genotypic data that can now be used to begin to identify
host genetic dispositions to COVID-19. The careful meth-
odological approach was carried out across a large geo-
graphical area to develop a biobank (the GCB), a registry
(the GCPR), and finally the resulting genetica data collec-
tion (the GCGDC). Following the timelines and milestones
of the GEN-COVID Multicenter Study (see Fig. 1), the
study has achieved a COVID-19 biobank, registry, and
genetic data collection linked to one another, providing a
high degree of confidence in sample and data integrity, and
open to the world for COVID-19 research at what may still
be considered an early point in this pandemic.
The GEN-COVID Biobank (GCB)
The GCB, a collection of biospecimens from patients
affected by COVID-19 and the associated GCPR were
established and maintained at the University of Siena using
Fig. 1 Timeline of GEN-COVID Multicenter study. A Main mile-
stones of the study with the timeline for the 22 Italian hospitals
(P: Promoter, Policlinico Santa Maria Alle Scotte, Azienda Ospeda-
liera Universitaria Senese, Siena; 1: San Matteo Hospital Fondazione
IRCCS, Pavia; 2:ASST Santi Paolo e Carlo, University of Milan, Italy;
3: Ospedale Maggiore di Crema, Italy; 4: ASST Valtellina e Alto
Lario, Sondrio; 5: University Hospital of Modena and Reggio Emilia,
Modena; 6: IRCCS, Lazzaro Spallanzani, Rome; 7: ASST-FBF-Sacco,
Milan; 8: Santa Maria Hospital, Azienda Ospedaliera di Perugia,
Perugia; 9: Treviso Hospital, Local Health Unit (ULSS) 2 Marca
Trevigiana, Treviso; 10: Ospedale dell’Angelo, ULSS 3 Serenissima,
Mestre; 11: Belluno Hospital, ULSS 1 Dolomiti, Belluno; 12: ASST
Spedali Civili Hospital, Brescia; 13: Policlinico San Martino Hospital,
IRCCS, Genova; 14: AORN dei Colli, Monaldi Hospital, Naples; 15:
A.O.R.N. “Antonio Cardarelli”, Naples; 16: Fondazione IRCCS Casa
Sollievo della Sofferenza Hospital, San Giovanni Rotondo; 17: IRCCS
Istituto G. Gaslini, Genoa; 18: CEINGE Biotecnologie Avanzate,
Naples; 19: San Donato Hospital, Arezzo; 20: Misericordia Hospital,
Grosseto; 21: Fondazione Policlinico Universitario Agostino Gemelli
IRCCS; 22: Luigi Curto Hospital, Polla (SA)). B Main milestones of
the study with the timeline for local health units (Continuity Assistance
Special Units, USCA) and departments of preventive medicine (1.
USCA, Chianciano; 2: USCA Sansepolcro; 3: USCA Siena; 4: USCA
Orbetello; 5: USCA Arezzo; 6: Department of preventive medicine
Senese, Siena; 7: Department of preventive medicine Aretino-Case-
ntino-Valtiberina, Arezzo; 8: Department of preventive medicine Alta
Val d’Elsa, Poggibonsi; 9: Department of preventive medicine Amiata
Senese e Val d’Orcia - Valdichiana Senese, Montepulciano). Other 11
USCA and 4 departments of preventive medicine have obtained IRB
approval and they are going to start sample collection.
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the infrastructure of an already well-established biobank (est.
1998) (http://www.biobank.unisi.it/ScegliArchivio.asp).
The Biobank is closely linked to national and interna-
tional biobanking efforts aimed at collecting high-
quality samples and patient data in a uniform manner and
ensuring their FAIR management. It is part of the BBMRI-
IT [12], EuroBioBank [13], Telethon Network of Genetic
Biobanks [14], and RD-Connect [15]. The biobank and
registry are ISO-certified (certificate 199556-2016-AQ-
ITA-ACCREDIA) and accredited according to SIGU (the
Italian Society of Human Genetics) requirements (Certifi-
cate 204107-2016-AQ-ITA-DNV).
Collected biological samples include peripheral blood,
plasma, serum, primary leukocytes, and DNA samples.
Samples were stored in a dedicated biobank section, while
associated clinical data were entered in the related registry.
The biobank and registry were organized according to the
highest scientific standards, preserving patients’ and citi-
zens’ privacy, while providing services to the healthcare
and scientific community to develop better treatments, test
diagnostic tools, and advance COVID-19 and coronavirus
research. Biobank personnel are responsible for sample
pseudonymization, storage, and insertion in the online
biobank catalog.
Geographical coverage
The GEN-COVID Multicenter Study reached a large
number of subjects throughout Italy. Tuscany, which is the
region in which the study is carried out, contributes pre-
sently 22.8% of enrolled patients. The Northern Italian
regions, particularly Lombardy and Venetia, currently
contribute 52.3% of enrolled patients (Fig. 2). This dis-
tribution reflects closely the incidence of SARS-CoV-2
infection per 100,000 inhabitants for each Italian region, as
updated to 4 July 2020 [3].
The GEN-COVID Patient Registry (GCPR)
From April 7, 2020 to July 16, 2020, the GCPR collected
clinical data from a total of 1033 Italian SARS-Cov-2 PCR-
positive individuals. For each individual, we collected
clinical information using standardized clinical schedules
(Supplementary Table 1). The study protocol also provides
access to patients’ medical records and continual clinical
data updating in order to secure continuity for patient
follow-up.
The mean age of the entire cohort is presently 58.7 years
(range 18–99). The cohort is presently predominantly male
(57.1%) with a mean age of 59.5 years (range 18–99); the
mean age of the females is 57.6 years (range 19–98)
(Table 1). About 40.3% of the cohort has no chronic con-
ditions. The overall case-fatality rate is 3.6% (37) deaths
among 1033 cases with a mean age of 75.2 years [range
62–91]. Regarding the ethnicity, the cohort is composed of
998 White (96.61%), 21 Hispanic (2.03%), 4 Black
(0.38%), and 10 Asian (0.96%) patients (Table 1).
Subjects have been divided into five qualitative severity
clinical categories depending on the need for hospitaliza-
tion, the respiratory impairment and, consequently, the type
of ventilation required: (1) hospitalized and intubated
(9.5%); (2) hospitalized and CPAP-BiPAP and high-flow
oxygen treated (18.4%); (3) hospitalized and treated with
conventional oxygen support only (31.55%); (4) hospita-
lized without respiratory support (14.8%); (5) not hospita-
lized pauci/asymptomatic individuals (25.75%) (Group 4 to
0 in Table 1).
Gender distribution was statistically significantly differ-
ent among the 5 groups (p value= 7.81 × 10−6). In the
group with high-care intensity (Group 4), 72.4% of subjects
were male, while in the group with the milder phenotype
(Group 0) 59.8% of subjects were female (Table 2).
Hyposmia and/or hypogeusia were present in 13.9% of
Fig. 2 Geographical coverage.
Comparison of GEN-COVID
geographical coverage (right)
and the incidence of SARS-
CoV-2 infection per 100,000
inhabitants by Italian provinces
(left).
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cases in Group 4, 25.3% in Group 3, 31.6% in Group 2,
19.3% in Group 1, and in 57.1% of Group 0. A slight
statistically significant difference among the 5 groups was
found regarding the presence of comorbidities (p value=
0.012). No statistically significant difference was present for
ethnicity and blood group distribution (Table 2).
Figure 3 shows the relationships between continually
updated laboratory variables from PCA. The first two
principal components explain 42.4% of the variability in the
data (PC1: 23.8%; PC2: 18.6%). Neutrophils, LDH, and D-
dimer appear to be positively correlated, while fibrinogen
and CRP, and hyposmia and the number of comorbidities
have been found, pairwise, to be negatively correlated. The
largest contributors to PC1 were LDH (24.4%), neutrophils
(24%), D-dimer (23.8%), and hyposmia (15.3%); the largest
contributors to PC2 were hyposmia (25.8%), fibrinogen
(22.1%), CRP (19.8%), and the number of comorbidities
(15.4%) (Fig. 3).
The continually updated laboratory values used in Fig. 3
can be further mined through clinical reasoning and repre-
sented as a binary clinical classification for organ/system
damage (Table 3).
Table 4 shows the prevalence of different organ/systems
damage in the five different clinical categories based on
respiratory failure (Table 4). Heart involvement was
detected in 55% of subjects in Group 4, 39% of subjects in
Group 3, 34.1% in Group 2, and 21.6% in Group 1. Liver
involvement was present in 72.4% of cases in Group 4,
59.3% in Group 3, 46% in Group 2, and 33.7% in Group 1.
Statistically significant difference among the 5 groups was
found for all organs/systems, except for the lymphoid
system.
Finally, the dendrogram in Fig. 4 shows how COVID-19
phenotypes can be distributed and clustered using the above
reported clinical data representations. In particular, Hier-
archical Clustering analysis identified five main clinical
Table 2 Cohort stratification by disease severity.
Subject characteristics Group 4 Group 3 Group 2 Group 1 Group 0 p value
Median age (range) 61.3 (29–79%) 65.3 (21–91%) 66.0 (21–99%) 55.86 (25–93%) 46.75 (19–72%) 1.35 × 10−7
Gender
Male (%) 72.4% 71.5% 59.8% 53.6% 40.2% 7.81×10−6
Female (%) 27.6% 28.5% 40.2% 46.4% 59.8%
Ethnicity
White 97% 97.3% 96.7% 96.6% 99.6%
Hispanic 2.% 1.1% 1.5% 2% 0.4% 0.731
Black 1.% 0 0.6% 0.7% 0
Asian 0 1.6% 1.2% 0,7% 0
Blood group
A 40.6% 46.6% 43.8% 43.25% 55%
B 8.7% 12.8% 16.1% 13.5% 10% 0.209
O 50.7% 39.8% 39.2% 43.25% 30%
AB 0 0.8% 0.9% 0 5%
Comorbidities
None 21.7% 18.8% 26.3% 32.4% 72.5%
One 34.8% 30.1% 26.7% 35.1% 17.5% 0.012
More than one 42% 45.1% 45.6% 28.4% 10%
Unknown 1.5% 6% 1.4% 4.1% 0
Table 1 Characteristics of cohort.
No. of subjects 1033









Clinical category no. (%)
Hospitalized intubated (Group 4) 98 (9.5%)
Hospitalized CPAP/BiPAP (Group 3) 190 (18.4%)
Hospitalize oxygen support (Group 2) 326 (31.55%)
Hospitalized w/o oxygen support (Group 1) 153 (14.8%)
Not hospitalized a/paucisymptomatic (Group 0) 266 (25.75%)
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categories and several subcategories: (A) severe multi-
systemic, with either thromboembolic (A1) or pancreatic
variant (A2); (B) cytokine storm, either moderate (B1) or
severe with liver involvement (B2); (C) mild, either with
(C1) or without hyposmia (C2); (D) moderate, either
without (D1) or with (D2) liver damage; (E) heart type,
either with (E1) or without (E2) liver damage (Fig. 4).
GEN-COVID Genetic Data Repository (GCGDR)
WES and Genotype (GWAS) data were generated within
the GCGDR. In order to be able to store and analyze the
massive amount of genomic data (mainly WES with cov-
erage > 97% at 20×, and prospetically including also WGS)
generated with the analysis of the entire cohort of samples
populating the biobank, we relied on the NIG. External
users can upload and analyze data using the NIG pipeline
by registering and creating a specific project. A section
dedicated to COVID-19 samples has been created within
the NIG database (http://nigdb.cineca.it/) that provides
variant frequencies as a free tool for both clinicians and
researchers.
The data from WES are available both in Variant Call
Format file or as binarized file, according to the different
classes of variants: (1) rare variants (minor allele frequency
(MAF) < 1%); (2) low-frequency variants (MAF < 5%); (3)
common polymorphisms (MAF > 5%) in either homo-
zygosity or supposed compound heterozygosity, with rare
or low-frequency variants. The distribution of these three
classes of variants according to mutated genes in our cohort
is shown in Supplementary Fig. 1.
From WES, 580,688 variants have been called: of these,
543,138 are SNP and 37,550 are MNP (multi-nucleotide
polymorphisms). Exonic SNPs were distributed over the 22
autosomes of the human genome, plus the sex chromo-
somes. The average missing rate was 0.01, with per-sample
maximum value of 0.017. 15,285 SNP loci had a missing
rate greater than 5%. The average MAF was 0.032 (std. dev.
0.091), with a right-skewed distribution (median MAF=
0.0007). Only 1,041 SNPs were monomorphic (0.2%), but
437,246 (80.5%) had a frequency <0.01. From the genotype
perspective, the average observed heterozygosity
was 0.047.
The data from high-density (700k) SNP genotyping are
also generated on the same cohort and shared with inter-
national collaborations, including the COVID-19 Host
Genetics Initiative (https://covid-19genehostinitiative.net/)
and with GoFAIR VODAN [16]. From this analysis, SNP
genotypes at 730,059 loci, distributed over the entire human
genome, have been obtained. The average missing rate was
0.015, with per-sample maximum value of 0.042. 11,163
SNP loci had a missing rate greater than 5%. The average
MAF was 0.113 (std. dev. 0.145), with a right-skewed
distribution (median MAF= 0.035). In total, 147,579 SNPs
were monomorphic (20.2%). From the genotype perspec-
tive, the average observed heterozygosity was 0.155.
Discussion
The COVID-19 pandemic represents an enormous chal-
lenge for the world’s healthcare systems. The healthcare
infrastructures and the working conditions are tremendously
challenged in many hospitals and direct patient care has
rightly been given the highest priority. The main public
health focus is on monitoring infection evolution in terms of
the number of new cases and the number of deaths as well
as the number of patients experiencing serious pulmonary
or systemic disease. To better characterize the current out-
break and facilitate prospective research to address the
current and possible future epidemics/pandemics, we set up
a COVID-19 biobank and patient registry where biological
samples and associated clinical data from patients are col-
lected in a standardized manner.
As expected, the majority of subjects in the group with
high-care intensity (Group 4) were males (72.4%) while in
the group with mild phenotype the majority of subjects were
females (59.2%). This is confirmatory of previously pub-
lished data reporting a predominance of males among the
most severely COVID-19 affected patients [17]. Among the
767 SARS-CoV-2 positive hospitalized patients in the
current cohort, 63% are males and 12.8% required
Fig. 3 PCA variables plot. Eigenvector-based coordinates of the
original variables in the two-dimensional space defined by the first two
principal components. The relative position of the clinical variables
reflect their relationship (positive correlated variables point to the same
side of the plot; negative correlated variables point to opposite sides of
the plot), while the length of the arrow is proportional to their con-
tribution to the principal components.
752 S. Daga et al.
intubation. This is in line with the distribution of the Italian
population of hospitalized COVID-19 patients [3] under-
lining the representativeness of our cohort.
Heart involvement was detected in the majority of severe
cases (Group 4), confirming again a recent report [18].
Hospitalized SARS-CoV-2 positive patients (Group 2 to 4)
have multiple-organ involvement: in particular, heart, liver,
pancreas, and kidney. In line with our previous data and
with literature findings, this confirms that COVID-19 is a
systemic disease rather than simply a lung disorder [19, 20].
Clinical data representation and interpretation
Clinical data may be represented and consequently inter-
preted in different ways. The simplest way of representation
is using the raw data of laboratory/instrumental values. In
this case, reasoning about which value has to be considered
and/or at which time of clinical evolution the value needs to
be measured is necessary in order to have consistency within
the cohort. PCA analysis using the WORSEN score at the
time of admission has shown the expected variability with
hyposmia to be juxtaposed to the number of comorbidities
and thus representing a marker of less severity. The fibri-
nogen value is juxtaposed to inflammatories markers, such
as CRP (and D-Dimer and LDH) because it is consumed
during the prothrombotic state. We can conclude that such
raw laboratory values are fairly good for representing the
clinical variability of the cohort in classical PCA analysis.
A more elaborate way of representing clinical data is to
filter the raw laboratory/instrument values by clinical rea-
soning, which often requires a face-to-face meeting with
organ reference specialists and direct access to the patients’
medical records. The proposed mediation of such a clinical
methodology for COVID-19 is represented in Table 3 and its
distribution against lung dysfunction synthesized in Table 4.
Involvement of relevant organs or systems is represented
in binary and is then used for representing COVID-19 as a
systemic disorder (Fig. 4). We propose this representation
Table 3 Binary clinical classification.
Organ/system Value Rule Clinical Interpretation
Lung 1, 0 1 if severity grading 4–2 and 0 if severity grading 1–0 Lung disease
Heart 1, 0 1 if cTnT > reference value or NT-proBNP gender
specific reference value or Arrhythmia
Heart disease
Liver 1, 0 1 if ALT and AST > gender-specific reference value Liver disease
Pancreas 1, 0 1 if lipase and/or pancreatic amylase > or < specific
reference value
Pancreas disease (either inflammation or
depletion)
Kidney 1, 0 1 if creatinine > gender-specific reference value Kidney disease
Lymphoid system 1, 0 1 if NK cells < reference value or CD4 lymphocytes <
reference value
Innate and adaptive immune deficit
Olfactory/gustatory system 1, 0 1 if hypogeusia or hyposmia Olfactory and Gustatory deficit





1, 0 1 if IL6 > reference value or LDH and CRP >
reference value
Hyperinflammatory response
cTnT cardiac Troponin T, NT-proBNP N-terminal (NT)-pro hormone BNP, ALT Alanine transaminase, AST Aspartate transaminase, CD4 CD4+
T cells, NK Natural killer, IL6 Interleukin 6, LDH lactate dehydrogenase, CRP c-reactive protein.
Table 4 Cohort systemic description.
Organ/system involvement Group 0 Group 1 Group 2 Group 3 Group 4 p value
Heart disease 0a 0.216 0.341 0.390 0.550 0.00016
Liver disease 0a 0.337 0.460 0.593 0.724 2.96 × 10−33
Pancreas disease 0a 0.054 0.073 0.218 0.304 7.15 × 10−5
Kidney disease 0a 0.121 0.244 0.278 0.434 0.0117
Innate and adaptive immune deficit 0a 0.202 0.138 0.270 0.507 0.229
Olfactory/gustatory deficit 0,4 0.162 0.225 0.157 0.086 0.0011
Thromboembolism 0a 0.040 0.073 0.097 0.318 4.2 × 10−7
Hyperinflammatory response NA 0.081 0.152 0.278 0.492 2.02 × 10−5
NA not applicable.
aAssigned on clinical ground.
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as one of the best, being closer to the real complexity of the
disease. It should be considered for use in further data
mining and correlation with genetic data. The emerging
clinical categories from Hierarchical Cluster Analysis point
to specific types and subtypes that are more likely to have
common genetic factors.
As unmasked by our dendrogram (group A), there is
indeed a growing body of evidence suggesting that, in
Fig. 4 Phenotypic clustering of COVID-19 patients. A Dendrogram
of COVID-19 patients’ clinical phenotypes by hierarchical clustering
of organ/system involvement. B Drawing of the above reported graph
helping interpretation and simplification in the main branch of the tree.
A1 severe multisystemic with either thromboembolic; A2 severe
multisystemic with pancreatic variant; B1 cytokine storm with mod-
erate liver involvement; B2 cytokine storm with severe liver involve-
ment; C1 mild with hyposmia; C2 mild without hyposmia; D1 moderate
without liver damage; D2 moderate with liver damage; E1 heart with
liver damage; E2 heart without liver damage.
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addition to the common respiratory symptoms (fever,
cough, and dyspnea), COVID-19 severely-ill patients can
often have symptoms of a multisystemic disorder [21].
Multiple organ failure due to diffuse microvascular damage
is an important cause of death in COVID-19 severely
affected patients [22]. In line with our definition of an
A1 subgroup, a retrospective study on 21 deaths after
SARS-Co-V2 infection recently reported that 71% of the
patients who died had disseminated intravascular coagula-
tion (DIC), while the incidence of DIC in surviving patients
was 0.6% [23]. These data suggest that DIC is an important
risk factor for increased in‐hospital mortality and special
attention should be paid to its early diagnosis and treatment.
While a debate still exists about the significance of pan-
creatic enzyme elevations during COVID-19 infection and
the capability of SARS-CoV-2 virus to induce pancreatic
injury due to cytotoxic effects [24, 25], it is worth noting that
among patients with a multisystemic involvement we
observe a subclass of individuals (group A2) with pancreatic
damage, likely suggesting a secondary effect of SARS-CoV-
2 infection on a subgroup of genetically predisposed indi-
viduals. Inflammatory cytokine “storm,” has been reported
as playing a key role in the severe immune injury to the
lungs caused by T‐cell overactivation (group B) [26]. While
some investigators have suggested a potential mechanism of
myocardial injury due to COVID‐19‐induced cytokine storm
that is mediated by a mixed T helper cell response in
combination to hypoxia [27] our findings indicate rather a
distinct class of patients, (group E) presenting with heart
involvement in the absence of an inflammatory cascade.
This would tend to support the hypothesis that SARS‐CoV‐2
may directly damage myocardial tissue and induce a major
cardiovascular event. Thus, as currently recommended, our
research reinforces the need to monitor plasma cTnT and
NT‐proBNP levels in COVID‐19 patients. In line with cur-
rent evidence [28, 29], although liver injury seems to occur
more frequently among critically ill patients with COVID‐19
(group B), it can also be present in non-critically ill patients
(groups D and E) and, as suggested, it could be mostly
related to prolonged hospitalization and viral shedding
duration. This allows defining, for each group, a clinical
subclass according to this organ involvement.
A recent extensive review determined the prevalence of
chemosensory deficits based on pooling together 42 studies
reporting on 23,353 patients [30]. Estimated random pre-
valence was 38.5% for olfactory dysfunction, 30.4% for
taste dysfunction, and 50.2% for overall chemosensory
dysfunction. No correlation with age was detected, but
anosmia/hypogeusia decreased with disease severity and
ethnicity turned out to play a significant role with Cauca-
sians having a three to six times higher prevalence of che-
mosensory deficits than East Asians. In accordance with
evidence found in the literature, hyposmia was mostly
represented among patients in group C with mild clinical
symptoms [31].
Genetic data representation and interpretation
Similar to the clinical data, large aggregates of genetic data
derived from WES may be represented, and consequently
interpreted, in different ways. After variant calling, it is
possible to use data as such, or variants can be prioritized
and filtered according to standard bioinformatics procedures
[32], such as damaging effect predictions, healthy popula-
tion allele frequency, and gene constraints to variation.
Alternatively, it is also possible to represent data in a
binary mode as follows: (1) select missense, splicing, and
loss of function variants below 1% (rare variants); (2) select
missense, splicing, and loss of function variants between 1
and 5% (low frequency variants); (3) select missense,
splicing, and loss of function variants above 5% (common
polymorphisms) in either homozygosity or supposed com-
pound heterozygosity with rare or low frequency variants.
The majority of patients showed about 3% of mutated genes
in the above class (1), 5% in class (2), and 28% in class (3)
variants (Supplementary Fig. 1A). No patients showed
variants in more than 8000 genes (Supplementary Fig. 1B).
Protein interaction network and pathway analysis have been
widely used to uncover and describe genetic relationships in
complex diseases, such as cancer [33, 34]. For example,
overrepresentation analysis of the biological processes and
pathways significantly affected by mutations will be instru-
mental to empower the statistical detection of genetic signatures
associated to specific COVID-19 phenotypes and to reduce the
number of parameters to consider (e.g. dimensionality reduc-
tion) with the purpose of developing robust algorithms for the
prediction of genetic susceptibility to COVID-19 infection and
response. Variants, genes, or biological processes will be
employed as features to train interpretable, supervised machine
learning classifiers (e.g., gradient boosting decision trees
[35, 36]), which will ease the identification of the genetic
factors associated with clinical phenotypes.
While data collection is being consolidated and brought
to completion according to the study design, we have
started to work on a relatively new methodology based on
topological data analysis to provide a detailed multi-
dimensional and multiscale exploration of the whole-exome
data that can drive an AI selection of genes that provide
higher predictive power in a machine learning model. The
method will be presented, together with the results, in a
forthcoming paper.
Post-Mendelian model of complex diseases
Previous attempts to interpret the genetic bases of complex
disorders have failed with very few exceptions, even in
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those disorders in which (like COVID-19) twin studies
demonstrated a very high rate of heritability, such as in
psychiatric disorders. The reason for this story containing
such a lack of scientific success resides in several weak
points in the overall genetic approach to complex diseases:
(1) the method used to represent the complexity of the
phenotype; (2) the procedure employed to represent the
huge amount of different genetic data; and (3) the absence
of a robust mathematical model able to interpret genetic
data in non-Mendelian (non-rare) disorders. This paper
provides a contribution to the first 2 points, likely paving
the way for a solution to the third.
Frequently the phenotype of common (complex) dis-
orders is oversimplified, thus attenuating reliable corre-
lation with genetic data. Limiting the representation to
differences of single parameters, such as respiratory
assistance (intubation, CPAP-BiPAP, oxygen supple-
mentation, etc.), is a possible trap for studies on complex
disorders as may be the case with COVID-19. Similarly,
genetic data are often too large to be mined and frag-
mented in different non communicating methods, betting
on either the power of common polymorphisms (GWAS)
or the power of variant accumulation (burden gene test for
WES). The binary representation we are proposing here,
together with network propagation for feature reduction,
and followed by machine learning approaches, may help
in this task. A rare disorder called TAR (OMIM # 274000)
is teaching us that combinatorial rules of rare variant(s)
with more common polymorphism(s) is what we are
looking for [37, 38].
The GEN-COVID Multicenter Study with its Registry
(GCPR), Biobank (GCB), and GCGDR is structured to
continually link with leading European and international
research organizations, public and private, as well as with
regulatory and public health authorities for developing
COVID-19 and SARS-related medicines research and
treatment protocols. The success of the developing research
and understanding of COVID-19 and the underlying SARS-
CoV-2 virus will rely in large part on human biological
materials and patient-level data that is comprehensively
collected and systematically organized with careful atten-
tion to sample and data integrity as well as the FAIR Data
Principles. Improving diagnostics, developing existing or
new therapeutics, improving treatment protocols, and even
developing public health policies relies upon a foundation
of evidence that requires the comprehensive, patient, and
systematic collection and organizing of COVID-19 patient
biological samples and data of high integrity, confidence,
and interoperability. The GEN-COVID Multicenter Study’s
GCPR, GCB, and GCGDR present a model that can be
further explored as a systematic approach to sample and
data collection while also being immediately deployable in
our collective fight against COVID-19.
Data availability
The data and samples referenced here in the GEN-COVID
Patient Registry and the GEN-COVID Biobank are
available for consultation.
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